Reply to "Myocarditis following mRNA-Based COVID-19 Vaccines: Correspondence"
Cardiology
.
2022;147(4):419-420.
doi: 10.1159/000524049.
Epub 2022 Mar 15.
Authors
Lauri Käsk
1
,
Terje H Larsen
2
3
,
Ronak Rajani
4
5
,
Sahrai Saeed
2
Affiliations
1
Department of Heart Disease, Haukeland University Hospital, Bergen, Norway, lauri.kask@helse-bergen.no.
2
Department of Heart Disease, Haukeland University Hospital, Bergen, Norway.
3
Department of Biomedicine, University of Bergen, Bergen, Norway.
4
Cardiothoracic Centre, Guy's & St Thomas' NHS Foundation Trust, London, UK.
5
School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
PMID:
35290979
DOI:
10.1159/000524049
No abstract available
Publication types
Letter
Comment
MeSH terms
COVID-19 Vaccines / adverse effects
COVID-19* / prevention & control
Humans
Myocarditis* / etiology
RNA, Messenger
Substances
COVID-19 Vaccines
RNA, Messenger